CTXR MAJOR NEWS! DMC meeting in next ten days. Share price projection from current price at high of $8.00 (and savvy investors know these analyst projections can be a lowball figure). Mino-Lok has worldwide formulation patent through 2036 with no competition. Hospitals will have to have Mino-Lok, CEO stated the people who write the standards of care are on board and is the new standard of care. CEO has brought recognition to brands such as Aveeno, Oral B, Vicodin. Mino-Lok received QIDP designation and FDA fast track. Phase 2b demonstrated 100% efficacy rate vs today's 18% serious adverse rate. CVC complications cause very high morbesity rates, tens of thousands of dollars in procedures, hefty hospital fines. Insider ownership at 6-10% proves this team of top tier doctors believes in the soon successful Mino-Lok product. Three manufactured runs are packaged on shelves in inventory ready to go the second FDA approves. In my experience with blind study trials, when they show success, the wealthy doctors and surgeons who see the results from successful blind studies upon finality, buy up hundreds of thousands of these undervalued stocks such as CTXR. When we start seeing dozens of orders for 100,000 to 500,000, you know that AT the LEAST several of the blind studies have passed the success mark with flying colors. I see this stock being a minimum of 10.50 by EOY, 13-17 in 2021 without the Lidocream product or catalysts. 37.00 a share by 2022. In 5 years my guess from past similar stocks and products in pipeline and this CEO, I see 75/share 80+ buyout. Do your own DD. Investing always has risks. I am an investor proud to back a company that will save so many lives.
